D-penicillamine-induced pemphigus successfully treated with combination therapy of mizoribine and prednisolone.
A 63-year-old woman had D-penicillamine-induced pemphigus with a high index value of circulating autoantibodies against desmoglein 1. Because of the lack of response to prednisolone monotherapy, the patient was treated with a combination therapy of mizoribine and low-dose prednisolone. The skin eruption was improved by this combination with a declined value of circulating anti-desmoglein 1 antibody. Currently, a remission of 2 months has been achieved, and prednisolone could be tapered.
Sugita
K
K
Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan. k-sugita@med.uoeh-u.ac.jp
Hirokawa
H
H
Izu
K
K
Tokura
Y
Y
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008875:Middle Aged; D010392:Pemphigus / Q000139:chemically induced* / Q000188:drug therapy; D010396:Penicillamine / Q000009:adverse effects* / Q000627:therapeutic use; D011239:Prednisolone / Q000008:administration & dosage; D012263:Ribonucleosides / Q000008:administration & dosage
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D012263:Ribonucleosides; C010052:mizoribine; D011239:Prednisolone; D010396:Penicillamine